Clinical Trial Update: A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH) [Phase 3]

View source ↗

Summary

Phase 3 trial update for Enlicitide Decanoate (MK-0616), an oral PCSK9 inhibitor, in adults with heterozygous familial hypercholesterolemia, with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Hypercholesterolemia
• Hypercholesterolemia

Drugs mentioned

• Enlicitide Decanoate (MK-0616) (Enlicitide Decanoate)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hypercholesterolemia, Familial Hypercholesterolemia | Phase 3 | Status: COMPLETED | Results posted: 2026-02-24